NATALIZUMAB-RELATED PML 2 WEEKS AFTER NEGATIVE ANTI-JCV ANTIBODY ASSAY

作者：Brosseau Marie Sarah Gagne^*; Stobbe Gary; Wundes Annette

来源：Neurology, 2016, 86(5): 484-486.

DOI：10.1212/WNL.0000000000002330

Progressive multifocal leukoencephalopathy (PML) is a serious complication of natalizumab pharmacotherapy, caused by the JC virus (JCV), against which 60% of adults have detectable serum antibodies.(1) The most common symptoms of PML are cognitive impairment, motor dysfunction, visual abnormalities, and speech deficit.(2) Although the mortality rate of 23%(3) in natalizumab-associated cases is lower compared to PML from other causes, most survivors have a poor functional outcome.(4) As of March 3, 2015, Biogen had reported 541 cases of natalizumab-related PML. Of 278 cases with available data, only 2 were negative for anti-JCV antibody; these 2 patients had tests dating from 8 and 9 months prior to diagnosis.(3</SUP)

• 出版日期2016-2-2